Compare AGD & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGD | VYGR |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.1M | 232.4M |
| IPO Year | N/A | 2015 |
| Metric | AGD | VYGR |
|---|---|---|
| Price | $11.65 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.17 |
| AVG Volume (30 Days) | 61.2K | ★ 463.3K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $107.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.20 | $2.65 |
| 52 Week High | $9.78 | $7.44 |
| Indicator | AGD | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 43.85 |
| Support Level | $11.31 | $3.91 |
| Resistance Level | $11.63 | $4.30 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 83.03 | 46.61 |
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors among others.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.